Sanofi (NASDAQ:SNY) Stake Lifted by Teachers Retirement System of The State of Kentucky

Teachers Retirement System of The State of Kentucky raised its stake in Sanofi (NASDAQ:SNY) by 23.2% during the second quarter, according to its most recent disclosure with the SEC. The fund owned 381,960 shares of the company’s stock after buying an additional 72,000 shares during the quarter. Teachers Retirement System of The State of Kentucky’s holdings in Sanofi were worth $18,533,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors also recently modified their holdings of SNY. Barrow Hanley Mewhinney & Strauss LLC lifted its holdings in Sanofi by 113.8% in the second quarter. Barrow Hanley Mewhinney & Strauss LLC now owns 5,943,547 shares of the company’s stock worth $288,381,000 after purchasing an additional 3,164,092 shares during the period. Magnetar Financial LLC boosted its holdings in shares of Sanofi by 1,153.1% in the second quarter. Magnetar Financial LLC now owns 2,506,286 shares of the company’s stock valued at $121,605,000 after acquiring an additional 2,306,286 shares in the last quarter. Bank of New York Mellon Corp increased its stake in shares of Sanofi by 19.0% during the second quarter. Bank of New York Mellon Corp now owns 8,594,740 shares of the company’s stock valued at $417,017,000 after acquiring an additional 1,370,232 shares during the period. Mondrian Investment Partners LTD raised its holdings in Sanofi by 43.1% during the first quarter. Mondrian Investment Partners LTD now owns 3,951,089 shares of the company’s stock worth $192,023,000 after purchasing an additional 1,190,141 shares in the last quarter. Finally, BNP Paribas Financial Markets lifted its position in Sanofi by 3,440.6% in the first quarter. BNP Paribas Financial Markets now owns 1,033,549 shares of the company’s stock worth $50,230,000 after purchasing an additional 1,004,358 shares during the period. Institutional investors and hedge funds own 10.04% of the company’s stock.

Sanofi Stock Performance

SNY stock opened at $57.31 on Wednesday. The firm has a 50 day simple moving average of $55.31 and a 200 day simple moving average of $50.97. Sanofi has a 52 week low of $42.63 and a 52 week high of $58.97. The stock has a market cap of $145.43 billion, a P/E ratio of 28.80, a P/E/G ratio of 1.62 and a beta of 0.60. The company has a debt-to-equity ratio of 0.17, a quick ratio of 0.65 and a current ratio of 1.00.

Sanofi (NASDAQ:SNY) last posted its quarterly earnings results on Thursday, July 25th. The company reported $0.93 EPS for the quarter, beating the consensus estimate of $0.88 by $0.05. Sanofi had a net margin of 9.60% and a return on equity of 26.29%. The business had revenue of $10.75 billion for the quarter, compared to analysts’ expectations of $16.86 billion. During the same period in the previous year, the company posted $0.95 EPS. Sanofi’s revenue was up 7.8% on a year-over-year basis. Research analysts anticipate that Sanofi will post 4.26 earnings per share for the current fiscal year.

Analysts Set New Price Targets

SNY has been the topic of several research analyst reports. StockNews.com upgraded Sanofi from a “buy” rating to a “strong-buy” rating in a research report on Wednesday. Citigroup raised Sanofi to a “strong-buy” rating in a report on Tuesday, September 17th. Finally, Argus boosted their target price on Sanofi from $55.00 to $60.00 and gave the stock a “buy” rating in a research report on Friday, July 26th. Three equities research analysts have rated the stock with a hold rating, one has given a buy rating and two have assigned a strong buy rating to the stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $57.50.

Sanofi Company Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.